Vimarsana
Biggest News Aggregation in the World

Page 26 - Cellular Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cellular Therapy Today - Breaking & Trending Today

RH and Caviar, the Bettencourt Affair Streams, Gabriela Hearst Parties – WWD - Vimarsana News

RH and Caviar, the Bettencourt Affair Streams, Gabriela Hearst Parties – WWD

RH has unveiled a new Champagne & Caviar Bar, Netflix dissects the Bettencourt Affair, Gabriela Hearst celebrated her new L.A. store

Source: wwd.com
Prada Supports MSK Society's Annual Gala – WWD - Vimarsana News

Prada Supports MSK Society's Annual Gala – WWD

The gathering at The Plaza hotel raised more than $600,000.

Source: wwd.com
FDA Accepts IND for Novel CDH17-Targeted CAR T-Cell Therapy for Advanced Gastrointestinal Cancers - Vimarsana News

FDA Accepts IND for Novel CDH17-Targeted CAR T-Cell Therapy for Advanced Gastrointestinal Cancers

The FDA has cleared the investigational new drug application for CHM 2101, a novel CDH17-targeted CAR T-cell therapy, for the treatment of patients with gastrointestinal cancers.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript - Vimarsana News

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript

Operator: Hello, and thank you for standing by. Welcome to the Allogene Therapeutics Third Quarter 2023 Conference Call.

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT - Vimarsana News

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...